Literature DB >> 10102344

Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study.

A Niezabitowski1, K Czajecki, J Ryś, A Kruczak, A Gruchała, A Wasilewska, B Lackowska, A Sokołowski, W Szklarski.   

Abstract

BACKGROUND AND OBJECTIVES: Depth of invasion and stage of the disease are established prognostic indicators in cutaneous malignant melanoma. The role of other parameters is still an open problem.
METHODS: In 93 consecutive patients with cutaneous malignant melanoma, the level of invasion, tumor thickness, ulceration, vascular invasion, lymphoplasmocytic infiltrates, and mitotic index were evaluated by histology. Expression of Ki-67 and PCNA proliferative antigens together with vimentin, S100, and HMB 45 proteins were assessed by immunohistochemistry. RESULTS AND
CONCLUSIONS: Disease-free and overall survival were correlated with tumor stage, tumor thickness, level of invasion, macroscopic pattern, ulceration, vascular invasion, expression of HMB 45, PCNA, and Ki-67/MIB1. Stage, HMB 45, and PCNA were independent prognostic factors for disease-free survival, whereas tumor stage, tumor thickness, and expression of both proliferative antigens influenced overall survival independently. The variables studied demonstrated reciprocal correlation; therefore, analysis of many prognostic parameters in malignant melanoma could be recommended.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102344     DOI: 10.1002/(sici)1096-9098(199903)70:3<150::aid-jso2>3.0.co;2-z

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  14 in total

Review 1.  Construction and analysis of multiparameter prognostic models for melanoma outcome.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  Methods Mol Biol       Date:  2014

Review 2.  Tissue prognostic biomarkers in primary cutaneous melanoma.

Authors:  Mario Mandalà; Daniela Massi
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

3.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

Review 4.  Transcription factors and other dysregulated proteins in melanoma prognosis.

Authors:  J M Karjalainen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

5.  Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.

Authors:  Hollis Viray; William R Bradley; Kurt A Schalper; David L Rimm; Bonnie E Gould Rothberg
Journal:  Arch Pathol Lab Med       Date:  2013-08       Impact factor: 5.534

Review 6.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

Review 7.  Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy.

Authors:  Nikolas K Haass; Keiran S M Smalley
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

8.  Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.

Authors:  Bonnie E Gould Rothberg; Christopher B Moeder; Harriet Kluger; Ruth Halaban; David E Elder; George F Murphy; Alexander Lazar; Victor Prieto; Lynn McDivitt Duncan; David L Rimm
Journal:  Mod Pathol       Date:  2008-06-13       Impact factor: 7.842

9.  Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression.

Authors:  G E Piérard
Journal:  ISRN Dermatol       Date:  2012-01-11

10.  Ki67 antigen as a predictive factor for prognosis of sinonasal mucosal melanoma.

Authors:  Dong-Kyu Kim; Dae Woo Kim; Si Whan Kim; Dong-Young Kim; Chul Hee Lee; Chae-Seo Rhee
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-12-26       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.